- Conditions
- Transformed Migraine, Chronic Daily Headache
- Interventions
- SPG Block with 5% Lidocaine gel, Amitriptyline
- Procedure · Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Focal Epilepsy
- Interventions
- 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, Placebo
- Drug
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 7
- States / cities
- Miami, Florida • Miami Lakes, Florida • Naples, Florida + 4 more
- Conditions
- Temporal Lobe Epilepsy
- Interventions
- High-Impact Aerobic Exercise, Low-Impact Aerobic Exercise
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Partial Seizures, Epilepsies, Partial
- Interventions
- pregabalin, placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 26
- States / cities
- Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more
- Conditions
- Epilepsy
- Interventions
- Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
- Other · Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
- Conditions
- Epilepsy, Epilepsy, Temporal Lobe, Partial Epilepsy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 8 Years to 99 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Epilepsies, Partial
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Epilepsy
- Interventions
- Brivaracetam
- Drug
- Lead sponsor
- UCB Pharma SA
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more
- Conditions
- Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure, Fall Due to Seizure
- Interventions
- Hövding inflatable helmet
- Device
- Lead sponsor
- Michael A. Gelfand, MD, PhD
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Seizure Disorder, Partial
- Interventions
- Pregabalin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 97
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 71 more
- Conditions
- Epilepsies, Partial
- Interventions
- Placebo, Pregabalin
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 1 Month to 16 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 10 more
- Conditions
- Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy), Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C)), Alpha-Dystroglycanopathy (Fukuyama CMD), Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I)), Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K)), Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M)), Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N)), Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O)), Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T)), Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U)), Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related), Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB)), Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS)), Choline Kinase B Receptor - CHKB, Collagen VI Related Disorders, Collagen XII Related Disorders, Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive), Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID), Congenital Muscular Dystrophy With Joint Hyperlaxity, Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1, Emery-Dreifuss Muscular Dystrophy, GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement, LMNA Related Disorders, Merosin Deficient CMD (Full or Partial), Nesprin Related MD (SYNE1), SELENON Related Disorders (Previously Known as SEPN1), SELENON Related Myopathy (Aka SEPN1), Telethonin CMD, Congenital Myasthenic Syndrome, Limb-Girdle Muscular Dystrophy, LGMDD01 - DNAJB6 (Formerly LGMD1D), LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant), LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G), LGMDR08 - TRIM Related (Formerly LGMD2H), LGMDR09 - FKRP Related (Formerly LGMD2I), LGMDR10 - Titin (TTN) Related (Formerly LGMD2J), LGMDR11 - POMT1 Related (Formerly LGMD2K), LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M), LGMDR14 - POMT2 Related (Formerly LGMD2N), LGMDR15 - POMGnT1 Related (Formerly LGMD2O), LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P), LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q), LGMDR18 - TRAPPC11 Related (Formerly LGMD2S), LGMDR19 - GMPPB Related (Formerly LGMD2T), LGMDR20 - ISPD Related (Formerly LGMD2U), LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive), LGMDR23 - LAMA2 Related, LGMDR24 - POMGnT2 Related
- Interventions
- Not listed
- Lead sponsor
- Cure CMD
- Other
- Eligibility
- Not listed
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2029
- U.S. locations
- 1
- States / cities
- Lakewood, California
- Conditions
- Partial Epilepsies
- Interventions
- Lacosamide
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 40
- States / cities
- Irvine, California • Rancho Mirage, California • Clearwater, Florida + 35 more
- Conditions
- Focal Epilepsy, Tonic-Clonic Seizures
- Interventions
- XEN1101
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more
- Conditions
- Focal Epilepsy, Generalized Onset Epilepsy, Sleep-related Epileptic Encephalopathy
- Interventions
- ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS), ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Epilepsy
- Interventions
- Brivaracetam
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 767 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 40 more
- Conditions
- Epilepsy
- Interventions
- Brivaracetam
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Fresno, California • Pasadena, California + 23 more
- Conditions
- Seizure Disorder
- Interventions
- External Trigeminal Nerve Stimulation (eTNS)
- Device
- Lead sponsor
- NeuroSigma, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Sylmar, California
- Conditions
- Rolandic Epilepsy, Rolandic Epilepsy, Benign, Centrotemporal Epilepsy, Centrotemporal; EEG Spikes, Epilepsy of Childhood, Epilepsy; Seizure, Epilepsy
- Interventions
- Closed loop auditory stimulation
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 4 Years to 18 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Focal Epilepsy
- Interventions
- ENX-101
- Drug
- Lead sponsor
- Engrail Therapeutics INC
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Downey, California + 31 more
- Conditions
- Epilepsy
- Interventions
- Eslicarbazepine acetate
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 96
- States / cities
- Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more
- Conditions
- Partial Epilepsy
- Interventions
- YKP3089, Placebo
- Drug
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 18 more
- Conditions
- Focal Epilepsy
- Interventions
- Acoustic Stimulation (AS), SHAM Stimulation
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Focal Onset Seizures
- Interventions
- RAP-219
- Drug
- Lead sponsor
- Rapport Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Boise, Idaho • Indianapolis, Indiana + 7 more